Natco Pharma, an India-based pharmaceutical company, received FDA approval yesterday for its glycopyrrolate oral tablets.
Natco Pharma's glycopyrrolate tablets, a generic version of the brand name drug Robinul, are used in conjunction with other medications to treat peptic ulcers. The tablets block the activity of acetylcholine in the body, decreasing stomach acid secretion.
Share prices of Natco Pharma rose 8 percent in response to news of the approval.
The drug manufacturer did not specify when the drug would hit the market.
More articles on supply chain:
Pa. cardiologist develops catheter inserted into the wrist
Medtronic's new surgical device earns FDA clearance for use in epilepsy clinical trial
Protestors at 'right to try' rally in D.C. want access to experimental drugs